Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Affymax has got $30m in development milestone payments from Takeda Pharmaceutical as part of the companies’ exclusive global agreement to develop and commercialise Hematide/peginesatide
Subscribe to our email newsletter
Hematide/peginesatide is Affymax’s investigational drug for the treatment of anemia in chronic renal failure patients.
Affymax and Takeda said that the payments were triggered by the achievement of database lock in the Pearl and Emerald Phase 3 clinical trials, which evaluated Hematide to treat anemia in chronic renal failure patients.
According to Affymax Hematide is the company’s first product candidate to enter the clinic and has been evaluated in Phase 3 clinical trials for the treatment of anemia associated with chronic renal failure.
Further, Affymax and Takeda Pharma are collaborating on the development of Hematide and is expected to co-commercialise the product in the US upon approval.
However, Takeda Pharma holds an exclusive license to develop and commercialise Hematide outside the US, including Japan.
Affymax is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions.